Abstract 180P
Background
Intrahepatic cholangiocarcinoma(iCCA) is the second most common primary hepatic malignancy after hepatocellular carcinoma (HCC), and is also a highly malignant type of tumor. It is necessary to identify novel therapeutic targets.Histidine phosphatase LHPP were reported as a tumor suppressor for Hepatocellular Carcinoma and cervical cancer. And low level LHPP enhanced cell progression and tumor formation, and was associated with poor prognosis. So, we hypothesized that LHPP might be also related to the tumorigenesis of iCCA.
Methods
We analyzed the expression and clinical significance of LHPP in TCGA cohort and patient tissues. We transfected the iCCA cell lines with LHPP over-expression lentivirus or small interfering RNA. Cell proliferation were evaluated with the CCK-8 and colony formation assays. Cell apoptosis was evaluated by Annexin V/PI staining.Transwell assays were performed to assess cell invasion. Gene Set Enrichment Analysis (GSEA) was performed to enrich genes associated with LHPP. Markers of EMT and TGFβ/SMAD3 signaling pathway were evaluated by real-time PCR and western blotting.
Results
In this study, we found the mRNA and protein level of LHPP were downregulated in tumor tissues, and low level LHPP predicted a poor survival. LHPP overexpression suppressed RBE and HCCC-9810 cells growth and colony formation, and moderately promote cell apoptosis and EMT. In contrast, accumulated cell growth, colony formation, cell invasion and EMT were observed in LHPP knock down cells. We divided samples from the TCGA-CHOL cohort into two sub-group (LHPP_low and LHPP_High) by medina expression of LHPP, and found that TGFβ signaling pathway was significantly activated in LHPP_low group. The expression of TGFβ1 was negatively correlated with LHPP. We found that the expression of TGFβ1, TGFβ1R and p-SMAD3 were downregulated in LHPP overexpression cells, and these proteins were upregulated in LHPP down-expression cells.
Conclusions
We demonstrated that LHPP also serve as a suppressor gene to inhibit cell proliferation, cell invasion and EMT. And low level LHPP which was observed in tumor tissues predicted a poor survival. Mechanically, low level LHPP activate TGFβ/SMAD3 signaling pathway.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fudan University Shanghai Cancer Center.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract